Related Experiment Video
Updated: Oct 30, 2025
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
Gabriel LaPlante1, Wei Zhang1,2
1Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Rd E, Guelph, ON N1G2W1, Canada.
The ubiquitin-proteasome system (UPS) is crucial for protein regulation and cancer. This review covers UPS inhibitors and targeted protein degradation strategies like PROTACs for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The ubiquitin-proteasome system (UPS) regulates cellular protein levels.
- UPS dysregulation is linked to various diseases, notably cancer.
- Cancer cells' high protein turnover increases their reliance on the UPS.
Purpose of the Study:
- To review small-molecule UPS inhibitors for cancer therapy.
- To highlight advancements in targeted protein degradation strategies.
- To discuss the therapeutic potential of targeting the UPS in cancer.
Main Methods:
- Review of existing literature on UPS inhibitors.
- Analysis of proteolysis-targeting chimeras (PROTACs) and their mechanisms.
- Discussion of clinical applications and future directions.
Main Results:
- Proteasome inhibitors are clinically successful in treating multiple myeloma.
- Small-molecule inhibitors targeting other UPS components are under development.
- PROTACs offer a promising approach for targeted protein degradation in cancer.
Conclusions:
- The UPS is a validated therapeutic target in oncology.
- Targeted protein degradation strategies, including PROTACs, represent a growing area for cancer drug development.
- Further research into UPS modulation holds significant potential for novel cancer treatments.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...